Is Biogen's Alzheimer's drug a historic achievement or red herring? There are plenty of opinions on both sides. Nonetheless, it received FDA approval despite an unanimous downvote from its own expert panel. What is going on here? No one knows, but to me, it just doesn't smell right. The subject of an email from Rick Berke, the executive editor of STAT, reads: 'A landmark day in Alzheimer's disease." Berke then linked to an article by Adam Feuerstein and Damian Garde, which, if it's less enthusiastic, it's not by much: "FDA grants historic approval to Alzheimer’s drug designed to slow cognitive...